MAPK3 and prostate cancer: As an initial approach to characterize ERK1/2 activation by OR51E2, we determined the effect of stimulation with increasing concentrations of β-ionone, a newly identified OR51E2 agonist (Neuhaus et al., 2009), in two prostate cancer cell lines (DU145 and LNCaP).